Table 2 The levels of cytokines in OA patients and control groups
Concentration (pg/ml), mean (95% CI) | |||||||
|---|---|---|---|---|---|---|---|
Plasma | Urine | Synovial fluid | |||||
Control | Knee OA | P-value | Control | Knee OA | P-value | Knee OA | |
CCL2 | 69.6 (42.2–97.1) | 86.1 (72.4–99.9) | 0.266 | 0.5 (0.2–0.8) | 3.5 (1.8–5.2) | < 0.0001*** | 567.2 (419.0–715.4) |
CCL3 | NA | NA | NA | NA | 51.4 (38.6–64.8) | ||
CCL4 | 222.0 (173.7–270.4) | 213.84 (192.3–235.4) | 0.631 | NA | NA | 296.7 (271.7–321.8) | |
CCL11 | NA | 93.9 (76.4–111.4) | 0.3 (0.15–0.38) | 3.4 (−1.4–8.2) | < 0.0001*** | 93.6 (84.2–102.9) | |
CCL19 | 152.9 (17.4–288.3) | 131.7 (36.2–227.3) | 0.079 | 0.06 (−0.01–0.12) | 0.3 (0.1–0.5) | 0.002** | 194.4 (91.2–297.6) |
CCL20 | NA | NA | NA | 1.1 (−0.7–2.8) | 97.3 (−46.8–241.5) | ||
CX3CL1 | 1305.3 (1061.0–1550.0) | 1266.6 (1125.0–1408.0) | 0.512 | 8.4 (7.0–9.7) | 11.9 (9.7–14.1) | 0.104 | 6930.8 (5760.0–8101.7) |
CXCL1 | NA | NA | NA | NA | 342.2 (−107.7–792.1) | ||
CXCL5 | 511.1 (−40.7–1063.0) | 388.9 (101.2–676.5) | 0.569 | NA | NA | 171.9 (93.4–250.4) | |
CXCL10 | 33.7 (14.4–53.0) | 42.3 (33.1–51.5) | 0.224 | 0.06 (0.02–0.09) | 0.1 (−0.01–0.3) | 0.569 | 143.2 (88.1–198.3) |
CXCL16 | 1052.7 (937.9–1167.0) | 1314.0 (1214–1414) | 0.005** | 0.05 (0.02–0.08) | 1.0 (0.4–2.0) | < 0.0001*** | 4467.4 (4131.9–4802.9) |
IL-1β | NA | NA | NA | 0.7 (−0.8–2.2) | NA | ||
IL-2 | NA | NA | NA | NA | 3.4 (2.6–4.3) | ||
IL-6 | NA | NA | NA | 0.5 (−0.06–1.0) | 243.4 (−158.6–645.3) | ||
IL-8 | NA | 3.1 (2.0–4.3) | 0.05 (−0.05–0.2) | 0.2 (0.09–0.4) | 0.003** | 103.1 (−22.0–228.2) | |
IL-12p70 | NA | NA | 0.7 (0.3–1.1) | 9.7 (−4.0–23.3) | 0.001** | NA | |
IL-15 | 2.8 (1.9–3.7) | 4.4 (3.6–5.2) | 0.038* | NA | 0.5 (−0.4–1.4) | 42.2 (38.4–46.0) | |
IL-33 | NA | NA | NA | NA | 4.27 (3.0–5.6) | ||
TNF-α | 1.2 (0.8–1.6) | 1.7 (1.3–2.1) | 0.108 | NA | NA | 2.1(0.9–3.3) | |